Neurocrine Stands By Vykat XR as Prader‑Willi Experts Raise Safety Flags

Highlights

Neurocrine continues to stand by Vykat XR, maintaining that the drug has a positive benefit‑risk profile for patients with Prader‑Willi syndrome despite emerging safety signals.

Experts and patient groups warn of 7 deaths and over 100 serious adverse events reported to the FDA’s Adverse Event Monitoring System (AEMS) as of July 31, 2026, including edema, respiratory‑related complications, and cardiac events in Vykat‑treated patients.

The clinicians’ statement does not establish causality between Vykat XR and the reported deaths, but calls for heightened awareness, careful patient selection, closer monitoring, and updated guidance on fluid retention and cardiopulmonary risk, especially in patients with severe obesity, heart disease, untreated sleep apnea, or other comorbidities.

Neurocrine states it remains in close contact with the FDA, patient organizations, and prescribers, and may consider label changes or additional treatment guidance while continuing to promote Vykat XR as a major therapeutic advance for hyperphagia in Prader‑Willi syndrome.